Is there a generic version of Sotatercept-Winrevair on the market?

As of October 2025, Sotatercept-Winrevair has not been approved for marketing in China, so there are no related generic drugs on the market. Winrevair is an innovative drug approved by the US FDA in March 2024. It is mainly used for the treatment of patients with pulmonary arterial hypertension (PAH). The specification is usually an injection of 45mg/tube. Because it is a brand-new biological agent, its production process is complex and involves patent protection. Therefore, no other company has yet been able to launch a generic version that is identical to the original drug.

In overseas markets,Winrevair has begun to be used in clinical applications, but it is still in the stage of high-value innovative drugs, the price is relatively high, and its use must strictly follow the doctor's prescription and monitoring plan. Since this type of biologics involves complex protein engineering and stability control, the development of generic drugs is more difficult and requires strict bioequivalence testing to obtain approval. Therefore, the possibility of generic drugs appearing in the short term is low. In addition, sotercept is a drug related to rare diseases and pulmonary hypertension, and its market size is relatively limited, which also affects the research and development momentum of generic drugs to a certain extent.

For patients, the lack of domestic generic drugs means that the use of sotercept must rely on original imported drugs, usually obtained through overseas channels. This poses challenges to patient accessibility and treatment costs, so doctors need to comprehensively consider drug accessibility, patients' financial conditions, and disease severity in clinical decision-making. In the future, as more production processes mature and patents expire, generic drugs of Sotecept are expected to gradually emerge, thereby reducing treatment costs and expanding the scope of patient benefits.

To sum up, there are currently no generic drugs of Sotecept in the domestic market, and patients need to rely on original imported drugs. The main specifications are45mg/injection. As an innovative targeted biologic, its development and production threshold is high, and the emergence of generic drugs in the future may take several years. It will also provide more accessible treatment options for patients with pulmonary arterial hypertension.

Reference materials:https://www.drugs.com/mtm/sotatercept.html